Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

por Berruti, Alfredo, Fazio, Nicola, Ferrero, Anna, Brizzi, Maria Pia, Volante, Marco, Nobili, Elisabetta, Tozzi, Lucia, Bodei, Lisa, Torta, Mirella, D’Avolio, Antonio, Priola, Adriano Massimiliano, Birocco, Nadia, Amoroso, Vito, Biasco, Guido, Papotti, Mauro, Dogliotti, Luigi
Publicado 2014

Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life

por Faggiano, Antongiulio, Carratù, Anna Chiara, Guadagno, Elia, Tafuto, Salvatore, Tatangelo, Fabiana, Riccardi, Ferdinando, Mocerino, Carmela, Palmieri, Giovannella, Damiano, Vincenzo, Siciliano, Roberta, Leo, Silvana, Mauro, Annamaria, Tozzi, Lucia Franca, Battista, Claudia, De Rosa, Gaetano, Colao, Annamaria
Publicado 2015